News

Phlow Announces over $35M in Series B Funding to Improve the U.S. Medicine Supply Chain

Phlow Corp., a U.S.-based public benefit corporation and contract development and manufacturing organization (CDMO),  announced that it has closed a $36 million Series B capital raise as part of its mission to protect America’s medicine cabinet. Since its launch in 2020, Phlow has been working to leverage advanced development and manufacturing processes to re-imagine the domestic production of key starting materials (KSM), active pharmaceutical ingredients (API), and finished pharmaceutical products that are critical to U.S. healthcare.

The strategic capital raised will be leveraged by Phlow to expand its commercial offerings, including the rapid growth of its CDMO program, called cdmoX, that provides a range of customized services to pharmaceutical and biotech companies resulting in reduced production costs, decreased development time, improved quality, and lower negative environmental impact. Phlow’s U.S.-based R&D laboratory, co-located with the U.S. Pharmacopeia (USP) at the Advanced Pharmaceutical Development Center in Richmond, VA, along with its brand new manufacturing facilities in Petersburg, VA, will make it possible for Phlow’s customers to bring critical medicine supply chains back to the United States in order to help prevent future disruptions from public health threats, trade disputes, and geopolitical challenges. Further, by deploying state-of-the-art flow chemistry, continuous manufacturing technology, and other advanced manufacturing processes, Phlow’s goal is to help customers achieve faster regulatory approvals resulting in increased patient access to life-changing medicines and reduced drug shortages that continue to impact Americans.

“At Phlow, our U.S.-based public benefit corporation is focused firmly on impact, solving for critical pharmaceutical supply chain challenges by moving far beyond the boundaries of the status quo in pharmaceutical development and manufacturing. Our recent investment round further ensures our bold mission and progress towards helping to solve for drug shortage challenges while providing end-to-end solutions in the U.S. that are fully integrated, comprehensive, environmentally friendly and cost competitive,” said Eric Edwards, M.D., Ph.D., co-founder and CEO of Phlow.

“On behalf of our growing Phlow team, we are deeply appreciative that our investors have exhibited continued confidence and trust in not only our shared vision but our proven ability to execute,” said Dave Ryan, Phlow’s Chief Financial Officer. “Together, we are revolutionizing the science behind life-changing medicines and creating unprecedented levels of access that is helping to improve the health of our nation.”

Learn more here.

Recent News

04/24/2024

VIPC Names Joe Benevento as President & CEO

The Board of Directors of the Virginia Innovation Partnership Corporation (VIPC) has announced that it has unanimously selected Joe Benevento as President and CEO of VIPC. Benevento has led VIPC as Interim President and CEO since September 2023 and previously served as Deputy Secretary of Commerce and Trade for the Commonwealth of Virginia since 2022.

04/23/2024

AMPEL BioSolutions Selected as Member of Prestigious Federal Health Innovation ARPA-H Network

AMPEL BioSolutions has been selected as a member – or “spoke” – of the Customer Experience Hub of ARPANET-H, a prestigious nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).  This national effort is designed to accelerate commercialization of health breakthroughs for populations that urgently need them. The Customer Experience Hub in Dallas joins Boston

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous